A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

• Status: Completed
• Trial end date: 2018-10-16
• Target enrollment: 0
• Participant gender: All

Summary

This is a healthy volunteers study to assess the bioequivalence of vadadustat 450 mg tablets (Test A) compared to three 150mg tablets (Reference B). The study will also assess the effect of food on the bioavailability of vadadustat 450 mg tablet.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Akebia Therapeutics

Criteria

Inclusion Criteria:

• Male or female subjects between ≥18 years and ≤55 years of age

• Healthy subjects per Investigator judgment as documented by the medical history, physical examination, vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and general observations.

• Have a body weight ≥50 kg and body mass index (BMI) ≥18.5 kg/m2 to 29.5 kg/m2 inclusive

• Understands the procedures, provides ICF and willing to comply with study requirements

• Willing and able to comply with the requirements of the study protocol.

Exclusion Criteria:

• Current or past history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease.

• History of cancer (except non- melanoma skin cancer) or history of chemotherapy use.

• Any surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to gastric bypass surgery or gastric or duodenal ulcers.

• History of severe allergic or anaphylactic reactions. Chronic daily medication use.

• History of drug abuse Excessive alcohol consumption.

• Smoking and the use of nicotine-containing products

• Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro (blood) orange, or their associated products

• Participation in another clinical trial or exposure to any investigational agent.

• Donation of blood or significant blood loss or plasma donation.

• Any condition that would interfere with the ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.